| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CONSENSUS STATEMENT |
1 Departments of Endocrinology and 2 Ophthalmology, Orbital Centre, Academic Medical Centre, Amsterdam, The Netherlands, 3 Department of Endocrinology, Freeman Hospital, Newcastle upon Tyne, UK, 4 Department of Medicine I, Gutenberg University Hospital, Mainz, Germany, 5 University Department of Ophthalmology, Ahepa Hospital, Thessaloniki, Greece, 6 Department of Ophthalmology, Universite Catholique de Louvain, Brussels, Belgium, 7 Department of Ophthalmology, Royal Victoria Infirmary, Newcastle upon Tyne, UK, 8 Medical School, University of Newcastle upon Tyne, Newcastle upon Tyne, UK, 9 Department of Endocrinology, Panagia General Hospital, Thessaloniki, Greece, 10 Cardiff Eye Unit, University Hospital of Wales, Heath Park, Cardiff, UK, 11 School of Medicine, Cardiff University, Llandough Hospital, Cardiff, UK, 12 Departments of Endocrinology and 13 Neuroscience Section of Ophthalmology, University of Pisa, Pisa, Italy, 14 Service of Endocrinology, Centre Hospitalier Lyon-Sud, Lyon, France, 15 Department of Ophthalmology, Johannes Gutenberg-University, Mainz, Germany, 16 Department of Internal Medicine and Endocrinology, Basedowch, Kantonsspital, Olten, Switzerland and 17 Basedowch, ADMEDICO Augenzentrum, Olten, Switzerland
(Correspondence should be addressed to P Perros who is now at Endocrine Unit, Level 6, Freeman Hospital, Freeman Road, Newcastle upon Tyne NE7 7DN, UK; Email: petros.perros{at}ncl.ac.uk)
Introduction
The European Group on Graves’ Orbitopathy (EUGOGO) was established in order to promote better clinical care of patients with Graves’ orbitopathy (GO) (1, 2) and to facilitate research in this disease. EUGOGO believes that patients with GO should be managed in multidisciplinary clinics with input from endocrinologists and ophthalmologists, who have an interest and experience in managing this disease (3). Although the expertise of the clinicians is critical and the setting perhaps less so, evidence from other clinical disciplines would suggest that a dedicated multidisciplinary clinic results in better outcomes (4, 5). EUGOGO is aware that many patients with GO in Europe never reach specialist centres or are referred too late to benefit from treatments (6), which results in a suboptimal outcome and sometimes loss of vision. EUGOGO recommends that primary care physicians, general practitioners, general internists and specialists, who have no particular expertise in managing such patients, should refer all but the mildest cases of GO to tertiary centres with established multidisciplinary clinics for further assessment and management. Selecting which patients should be referred and with what degree of urgency, is challenging for the generalist. EUGOGO proposes a simple clinical tool, which can be completed in less than 5 minutes by any medically qualified person and can help to identify patients who merit urgent or routine referral (Table 1
).
|
Since 1999, EUGOGO has convened 11 meetings attended by endocrinologists and ophthalmologists from 12 major European centres all with extensive experience in managing patients with this condition. Several hundreds of ‘man-hours’ were dedicated to debating methods of assessment of patients with GO, including sessions using patients with various degrees of severity and activity, examined and scored by EUGOGO members. Based on this experience, EUGOGO has reached consensus on assessment of patients with GO and has embarked on randomised controlled clinical trials. EUGOGO believes that clinical examination is the cornerstone of the assessment of GO; clinically and scientifically meaningful data can be derived from careful, clearly defined clinical evaluations. Imaging of the orbits by CT or MRI scanning is recommended when the diagnosis is uncertain, in cases of apparently unilateral disease and suspected dysthyroid optic neuropathy (7). The role of serial orbital imaging by CT or MRI scanning in randomised controlled trials is uncertain, as the clinical importance of orbital volume changes is not yet defined and EUGOGO does not recommend these measurements as primary outcomes.
Assessments in routine clinical practice
The EUGOGO recommendations (Table 2) for assessing patients with GO are based on those of the sister thyroid societies published more than a decade ago (8) and apply both to routine clinical practice in the setting of specialist multidisciplinary clinics and to clinical research purposes. There are four principal advances compared to the previous recommendations of the sister thyroid societies: (a) in order to standardise the assessments of the subjective components of GO (soft tissue and inflammatory features), EUGOGO recommends specific methodology. This involves an examination protocol with a comparative photographic Colour Atlas (9, 10), which provides precise definitions for clinical signs and examples for grading their severity. Comparisons of the assessments and scores of several patients between EUGOGO members on the same day led to the conclusion that some features can be accurately categorised into more than one grade of severity, while others can only be reliably scored as ‘present’ or ‘absent’. (b) A validated disease-specific questionnaire for assessment of quality of life is included (10, 11). (c) Although statistical comparisons of individual severity or activity parameters between or within patient groups may be scientifically interesting and worthwhile, EUGOGO recommends an overall evaluation for clinical trials, as this is more clinically meaningful and relevant. Primary outcomes may usefully be divided into objective and subjective categories as the relationship between the two is complex but equally important (Table 3). (d) EUGOGO defines the overall beneficial response in an individual patient as an improvement of the objective parameter most relevant to the study in at least one eye without deterioration of any objective parameter in either eye. EUGOGO recognises that the overall outcome is influenced by several factors, including whether the intervention is medical or surgical as well as the selection criteria of the study population. Therefore, the above definitions should be viewed as a model that may be usefully adapted for any study design.
|
|
The management of patients with GO can be improved by properly designed and executed large-scale studies with adequate statistical power. The feasibility of rapid recruitment for multicentre trials has already been demonstrated (12). EUGOGO believes that the available methodology as outlined here can be used for clinical trials as well as for the routine clinical assessment of patients with GO and therefore will be of interest to those who manage patients with this condition.
The European Group on Graves’ Orbitopathy
EUGOGO is a multidisciplinary consortium of clinicians from European centres, who share a commitment to improve the management of GO, have a good track record in clinical research in this field, are regional or national referral centres for the treatment of this disease and manage patients in a multidisciplinary setting with input from endocrinologists and ophthalmologists.
Footnotes
References
This article has been cited by other articles:
|
|
 |
|
  P. Perros, C. Neoh, and J. Dickinson Thyroid eye disease BMJ, March 6, 2009; 338(mar06_1): b560 - b560. [Full Text]
|
|
|
|
 |
|
 L. Bartalena and M. L. Tanda Graves' Ophthalmopathy N. Engl. J. Med., March 5, 2009; 360(10): 994 - 1001. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bartalena, L. Baldeschi, A. Dickinson, A. Eckstein, P. Kendall-Taylor, C. Marcocci, M. Mourits, P. Perros, K. Boboridis, A. Boschi, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO Eur. J. Endocrinol., March 1, 2008; 158(3): 273 - 285. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Cozma, L. Zhang, J. Uddin, C. Lane, A. Rees, and M. Ludgate Modulation of expression of somatostatin receptor subtypes in Graves' ophthalmopathy orbits: relevance to novel analogs Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1630 - E1635. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Deceased. 